Rituximab-Based Regimens for Treatment of Primary Gastric Diffuse Large B-Cell Lymphoma / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 760-764, 2022.
Article
在 Zh
| WPRIM
| ID: wpr-939685
Responsible library:
WPRO
ABSTRACT
OBJECTIVE@#To analyze clinical response of the Rituximab-based chemotherapy and prognostic features in patients with primary gastric diffuse large B-cell lymphoma (PGDLBCL).@*METHODS@#From June 2008 to December 2020, the data of 53 PGDLBCL patients were analyzed retrospectively.@*RESULTS@#The median age was 46(25-77) years old in 53 patients including 35 males and 18 females. Stomachache is the most common symptom. The diagnosis were confirmed in 47 patients by endoscopic biopsy and 6 patients by surgery. Twenty-six patients had Ⅰ/Ⅱ1 stage (Lugano staging system) disease and 27 cases had II2/IV stage disease. All patients were treated with chemotherapy, including RCHOP (25/53) and R-DA-EPOCH (28/53). Complete remission rate was 79.2%(42/53). The 3-year and 5-year overall survival (OS) rates were 77.4% and 69.8%. Univariate analysis showed that lactate dehydrogenase(LDH), Lugano stage and lesion size affected OS. Multivariate Cox regression analysis revealed that IPI score and Lugano stage were independent prognosis risk factors affecting OS. The patients in the R-DA-EPOCH group presented better survival outcomes than those in the RCHOP group with late stage (P5-year OS=0.035).@*CONCLUSION@#Rituximab in combination with chemotherapy is the backbone of therapy for PGDLBCL. IPI score and Lugano stage are independent prognosis risk factors affecting OS of PGDLBCL. R-DA-EPOCH can be superior to R-CHOP as a first-line regimen in PGDLBCL patients with late stage.
Key words
全文:
1
索引:
WPRIM
主要主题:
Prognosis
/
Vincristine
/
Prednisone
/
Antineoplastic Combined Chemotherapy Protocols
/
Doxorubicin
/
Retrospective Studies
/
Lymphoma, Large B-Cell, Diffuse
/
Disease-Free Survival
/
Cyclophosphamide
/
Rituximab
研究类型:
Observational_studies
/
Prognostic_studies
限制:
Adult
/
Aged
/
Female
/
Humans
/
Male
语言:
Zh
期刊:
Journal of Experimental Hematology
年:
2022
类型:
Article